U.S. Markets closed

DaVita Partners Cureatr

Zacks Equity Research

DaVita, the dialysis unit of kidney care service provider, DaVita HealthCare Partners Inc. (DVA) entered into a strategic alliance with Cureatr with the aim to improve nationwide communication and care coordination among care teams at dialysis centers. Cureatr offers mobile care coordination solution for healthcare providers.

DaVita provides an extensive range of healthcare services to patients throughout the United States and abroad. However, it encounters serious care coordination challenges. Thus, in order to optimize care coordination and generate reports on key quality measures for improvement, it requires adequate technological support. Cureatr’s enterprise messaging and workflow navigation solutions will ensure better clinical information sharing for DaVita.

DaVita has already implemented Cureatr solutions in its operations in Atlanta and is upbeat on the prospects as it has received a favorable response. Additionally, the company aims to expand its scale of operations and eventually utilize Cureatr solutions in other locations.

This partnership will allow DaVita to offer the iPhone and web apps of Cureatr to its facility administrators, care managers, nurses and affiliated nephrologists. To improve communication within the dialysis care teams of DaVita, the provision will include Health Insurance Portability and Accountability Act (:HIPAA)-secure group messaging system with read receipts, secure photo sharing technology, and seamless integration with the existing scheduling and directory systems. This facilitates doctors, nurses and other care-team members to provide high quality care to their patients.

We believe that this partnership will auger well for DaVita as Cureatr’s proficiency will aid the company to overcome communication barriers and deliver more efficient patient care as well as induce growth.

Among its recent ventures, last week, DaVita and Myriad RBM entered into a strategic liaison to perform a protein biomarker discovery research. Myriad RBM is a wholly owned subsidiary of a leading molecular diagnostic company, Myriad Genetics Inc. (MYGN). The objective is to develop and introduce diagnostic tests into the market for the better treatment of dialysis patients.

DaVita currently carries a Zacks Rank #3 (Hold). Among others in the industry, China Cord Blood Corporation (CO) carries a Zacks Rank #2 (Buy) while Adus HomeCare Corporation (ADUS) carries a favorable Zacks Rank #1 (Strong Buy).

Read the Full Research Report on DVA

Read the Full Research Report on MYGN

Read the Full Research Report on ADUS

Read the Full Research Report on CO

Zacks Investment Research

More From Zacks.com